vs

Side-by-side financial comparison of Ascendis Pharma A/S (ASND) and FIRST COMMONWEALTH FINANCIAL CORP (FCF). Click either name above to swap in a different company.

Ascendis Pharma A/S is the larger business by last-quarter revenue ($267.3M vs $133.7M, roughly 2.0× FIRST COMMONWEALTH FINANCIAL CORP). On growth, Ascendis Pharma A/S posted the faster year-over-year revenue change (42.3% vs 13.0%). Over the past eight quarters, Ascendis Pharma A/S's revenue compounded faster (60.7% CAGR vs 5.5%).

Growth hormone therapy refers to the use of growth hormone (GH) as a prescription medication—it is one form of hormone therapy. Growth hormone is a peptide hormone secreted by the pituitary gland that stimulates growth and cell reproduction. In the past, growth hormone was extracted from human pituitary glands. Growth hormone is now produced by recombinant DNA technology and is prescribed for a variety of reasons. GH therapy has been a focus of social and ethical controversies for 50 years.

First Commonwealth Financial Corp is a Pennsylvania-based regional financial services holding company. It offers consumer and commercial banking products, loans, wealth management, and insurance services for individuals, small and mid-sized enterprises across central and western Pennsylvania and Ohio.

ASND vs FCF — Head-to-Head

Bigger by revenue
ASND
ASND
2.0× larger
ASND
$267.3M
$133.7M
FCF
Growing faster (revenue YoY)
ASND
ASND
+29.4% gap
ASND
42.3%
13.0%
FCF
Faster 2-yr revenue CAGR
ASND
ASND
Annualised
ASND
60.7%
5.5%
FCF

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
ASND
ASND
FCF
FCF
Revenue
$267.3M
$133.7M
Net Profit
$37.5M
Gross Margin
90.5%
Operating Margin
Net Margin
28.1%
Revenue YoY
42.3%
13.0%
Net Profit YoY
-16.3%
EPS (diluted)
$0.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASND
ASND
FCF
FCF
Q1 26
$133.7M
Q4 25
$267.3M
$137.9M
Q3 25
$230.7M
$136.0M
Q2 25
$170.7M
$131.0M
Q1 25
$109.0M
$118.0M
Q4 24
$187.8M
$120.4M
Q3 24
$62.5M
$121.2M
Q2 24
$38.9M
$120.2M
Net Profit
ASND
ASND
FCF
FCF
Q1 26
$37.5M
Q4 25
$44.9M
Q3 25
$-65.9M
$41.3M
Q2 25
$-42.0M
$33.4M
Q1 25
$-102.2M
$32.7M
Q4 24
$35.8M
Q3 24
$-107.1M
$32.1M
Q2 24
$-118.1M
$37.1M
Gross Margin
ASND
ASND
FCF
FCF
Q1 26
Q4 25
90.5%
Q3 25
89.5%
Q2 25
80.1%
Q1 25
82.6%
Q4 24
91.9%
Q3 24
80.6%
Q2 24
68.2%
Operating Margin
ASND
ASND
FCF
FCF
Q1 26
Q4 25
40.9%
Q3 25
5.1%
38.1%
Q2 25
-33.5%
32.1%
Q1 25
-103.2%
34.8%
Q4 24
37.1%
Q3 24
-167.3%
33.4%
Q2 24
-370.2%
38.7%
Net Margin
ASND
ASND
FCF
FCF
Q1 26
28.1%
Q4 25
32.5%
Q3 25
-28.5%
30.4%
Q2 25
-24.6%
25.5%
Q1 25
-93.7%
27.7%
Q4 24
29.8%
Q3 24
-171.5%
26.5%
Q2 24
-303.9%
30.9%
EPS (diluted)
ASND
ASND
FCF
FCF
Q1 26
$0.37
Q4 25
$0.44
Q3 25
$0.39
Q2 25
$0.32
Q1 25
$0.32
Q4 24
$0.35
Q3 24
$0.31
Q2 24
$0.36

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASND
ASND
FCF
FCF
Cash + ST InvestmentsLiquidity on hand
$665.3M
Total DebtLower is stronger
$154.9M
Stockholders' EquityBook value
$-175.8M
$1.6B
Total Assets
$1.4B
$12.3B
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASND
ASND
FCF
FCF
Q1 26
Q4 25
$665.3M
Q3 25
$582.2M
Q2 25
$533.6M
Q1 25
$559.4M
Q4 24
$604.3M
Q3 24
$675.6M
Q2 24
$279.4M
Total Debt
ASND
ASND
FCF
FCF
Q1 26
$154.9M
Q4 25
$261.7M
Q3 25
$262.1M
Q2 25
$262.4M
Q1 25
$262.7M
Q4 24
$263.0M
Q3 24
$136.3M
Q2 24
$136.6M
Stockholders' Equity
ASND
ASND
FCF
FCF
Q1 26
$1.6B
Q4 25
$-175.8M
$1.6B
Q3 25
$-188.0M
$1.5B
Q2 25
$-202.6M
$1.5B
Q1 25
$-205.0M
$1.4B
Q4 24
$-114.2M
$1.4B
Q3 24
$-105.1M
$1.4B
Q2 24
$-346.8M
$1.4B
Total Assets
ASND
ASND
FCF
FCF
Q1 26
$12.3B
Q4 25
$1.4B
$12.3B
Q3 25
$1.2B
$12.3B
Q2 25
$1.2B
$12.2B
Q1 25
$1.1B
$11.8B
Q4 24
$1.3B
$11.6B
Q3 24
$1.2B
$12.0B
Q2 24
$819.0M
$11.6B
Debt / Equity
ASND
ASND
FCF
FCF
Q1 26
0.10×
Q4 25
0.17×
Q3 25
0.17×
Q2 25
0.17×
Q1 25
0.18×
Q4 24
0.19×
Q3 24
0.10×
Q2 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASND
ASND
FCF
FCF
Operating Cash FlowLast quarter
$58.2M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASND
ASND
FCF
FCF
Q1 26
Q4 25
$58.2M
$187.5M
Q3 25
$49.5M
Q2 25
$30.4M
Q1 25
$-15.5M
$55.9M
Q4 24
$-330.7M
$129.5M
Q3 24
$53.6M
Q2 24
$22.7M
Free Cash Flow
ASND
ASND
FCF
FCF
Q1 26
Q4 25
$171.5M
Q3 25
Q2 25
Q1 25
Q4 24
$113.9M
Q3 24
Q2 24
FCF Margin
ASND
ASND
FCF
FCF
Q1 26
Q4 25
124.3%
Q3 25
Q2 25
Q1 25
Q4 24
94.6%
Q3 24
Q2 24
Capex Intensity
ASND
ASND
FCF
FCF
Q1 26
Q4 25
11.7%
Q3 25
Q2 25
Q1 25
Q4 24
12.9%
Q3 24
Q2 24
Cash Conversion
ASND
ASND
FCF
FCF
Q1 26
Q4 25
4.18×
Q3 25
1.20×
Q2 25
0.91×
Q1 25
1.71×
Q4 24
3.61×
Q3 24
1.67×
Q2 24
0.61×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons